The Outlook For The Pharmaceutical Industry Under Trump
Law360, New York (January 12, 2017, 1:30 PM EST) -- Mark P. Goodman
Jennifer L. Chu
Kevin A. Rinker
The 2016 election will have important consequences for the pharmaceutical industry. While President-elect Trump has now made key health care-related appointments and has issued several broad post-election statements related to health care reform, many unknowns remain.
Immediately after the election, the price of pharmaceutical and biotech companies generally rose. Investors have been optimistic that Mr. Trump's free-market, anti-regulation approach will benefit drug and biotech manufacturers.
While there is truth to this conventional wisdom, what we do know suggests that the reality will be more nuanced. We also know that changes won't be...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!